Enalapril and atenolol in essential hypertension: Attenuation of hypotensive effects in combination

L. M.H. Wing, J. P. Chalmers, M. J. West, A. E. Russell, M. J. Morris, M D. Cain, A J C Bune, D. O. Southgate

    Research output: Contribution to journalArticle

    41 Citations (Scopus)

    Abstract

    In 16 patients with essential hypertension the effects of enalapril 20 mg once daily were compared with those of atenolol 50 mg once daily, with the two drugs in combination and with placebo using a double-blind cross-over design with allocation of treatment order by randomised Latin squares. For each patient there were four treatment phases, each of four weeks duration, which together comprised a 2×2 factorial experiment. All blood pressure parameters were reduced in the three active treatment phases compared to placebo (p < 0.001). Supine blood pressures (group means) were 171/97 (placebo), 147/85 (enalapril), 154/84 (atenolol) and 144/78 (enalapril plus atenolol) (S.E.M. ± 2/± 1 -ANOVA), and standing blood pressures were 170/105 (placebo), 146/92 (enalapril), 154/92 (atenolol) and 147/86 (enalapril plus atenolol) (S.E.M. ± 3/+1). In the combination phase there was an additional hypotensive response but the potential fully additive effects of the two agents were attenuated by 30-50% The mechanism of the attenuated hypotensive effect of the combined agents has not been determined. Plasma atrial natriuretic peptide (ANP) concentration was doubled in the presence of atenolol (P < 0.01) suggesting that ANP may contribute to the hypotensive effect of the beta-blocker.

    Original languageEnglish
    Pages (from-to)119-133
    Number of pages15
    JournalClinical and Experimental Hypertension
    Volume10
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 1988

    Keywords

    • Angiotensin converting enzyme Inhibitors
    • Atenolol
    • Atrial natriuretic peptide
    • Blood pressure
    • Enalapril
    • Renin-angiotensin system

    Fingerprint Dive into the research topics of 'Enalapril and atenolol in essential hypertension: Attenuation of hypotensive effects in combination'. Together they form a unique fingerprint.

  • Cite this